Arena, Eisai ink Belviq deal with CVS; Teva chairman unloads $7M in shares; Actelion hikes dividend;

@FiercePharma: Perrigo sees growth, but its sales are trimmed by a hit to contract manufacturing. Story | Follow @FiercePharma

@TracyStaton: Double dose of Merck is too much for German version's CEO. Article | Follow @TracyStaton

@EricPFierce: The best biomedical research facilities in the US may not surprise you. Then again maybe it will. Report | Follow @EricPFierce

@GalenMoore: Particularly for drugmakers strong in diabetes, the Gulf region is a hotbed of activity. Story | Follow @GalenMoore

> Arena Pharmaceuticals ($ARNA) and its marketing partner, Eisai, said they made a deal with the pharmacy benefits manager CVS Caremark ($CVS) to make their weight-loss drug Belviq available to members. Report

> Israel-based Teva Pharmaceutical Industries ($TEVA) Chairman Phillip Frost sold shares worth $7 million, leaving him a stake of $500 million-plus. Report

> The Swiss drugmaker Actelion hiked its dividend by 20% after sales of its new drug, Opsumit, rose. Report

> Top executives from more than a dozen Indian drugmakers met with FDA Commissioner Margaret Hamburg in New Delhi to talk about manufacturing problems and agency oversight. Report

> Innovus Pharma tapped Lynnette Dillen to join the company as EVP and CFO. Release

> India's Aurobindo Pharma said its profit tripled for its fiscal third quarter. Report

Medical Device News

@FierceMedDev: St. Jude Medical's stock spiked again after an analyst upgrade. Story | Follow @FierceMedDev

@MarkHFierce: FierceBiotechResearch's latest--a look at the top 10 U.S. biomedical research institutions. Report | Follow @MarkHFierce

@MichaelGFierce: Sonrgy grabs rights to UCSD-created ultrasound-nanocarrier tech. Item from FierceDrugDelivery | Follow @MichaelGFierce

@EmilyWFierce: ConvaTec is closing its New Jersey facility and cutting jobs. Story | Follow @EmilyWFierce

> Two major Dx players in Brazil are on the cusp of major changes. Item

> Surgeons have implanted a 3-D-printed pelvis into a U.K. cancer patient. More

> Smiths Medical adds tracheostomy tubes designed for kids to standard product line. News

Biotech News

@FierceBiotech: Another 5 biotechs are queuing up for $278M in IPOs. Is this a bubble after all? More | Follow @FierceBiotech

@JohnCFierce: I'm happy to see the IPO boom, the rise in valuations and all that. But with booms, the bigger they are, the harder they fall. Don't forget. | Follow @JohnCFierce

@DamianFierce: The FDA is giving Sprout's female libido drug another shot in what is becoming a pretty interesting case study. Coverage | Follow @DamianFierce

@EmilyMFierce: The top 10 biomedical research organizations, ranked by NIH funding. Special report | Follow @EmilyMFierce

> The world's two Mercks squabble over who gets to be a household name. Story

> GlaxoSmithKline R&D chief touts the future of 'electroceuticals.' News

Biotech Research News

> The top 10 biomedical research institutions. Special Report

> CalTech drug delivery method halts HIV infection in mice. Article

> Nasal vaccine protects mice from West Nile virus. Story

> U.K. pledges to reduce use of animals for biomedical research. News

> Gates Foundation delivers an $11.8M grant to fuel tuberculosis R&D. Story

> New therapeutic target for multiple sclerosis could help repair damaged brain cells. Article

Pharma Manufacturing News

> FDA says products recalled by compounder are contaminated. News

> Teva, which has been tightening its supply chain, turns in a surprising financial report. Story

> Jazz is investing up to $68M to build its first manufacturing facility. Article

> Wockhardt's earnings crash under the weight of FDA bans. News

> The FDA reports far fewer new drug shortages, but the problem continues to grow. Article

> Novartis is expanding a plant in Singapore. Item

And Finally... Will Switzerland's new immigration limits force out expat execs? Report

Suggested Articles

Download our solutions overview to discover how CoverMyMeds can make a difference for your brand.

In a bladder cancer field chock-full of checkpoint inhibitors, Pfizer and Merck KGaA’s Bavencio has a chance to get ahead thanks to new data.

The FDA backtracked on its earlier testing and found NDMA contamination in the extended release formulation of certain generic versions of metformin.